"Could also be news on releif therapeutics" I believe so. The problem with not having institutional investors is getting slammed by fickle investors when the new flavor of the week comes in. I also have a small amount of HGEN and it is getting walloped as well.

The interesting thing about Relief and aviptadil is that it decreases Rantes, so the reason it seems to work is the same reason leronlimab works. But I believe leronlimab will work more efficiently and we are also further along in trials.

Dr. Yo said last night that there is room for multiple therapeutics.